ATLANTA, Oct. 24, 2024 – OncoLens, a leader in optimizing cancer treatment planning, has raised $16 million in a Series B round co-led by BIP Capital and Cross Border Impact Ventures. Oncolens has been a BIP Ventures portfolio company since 2019. This round of funding comes on the heels of OncoLens coming in at No. 1296 on the Inc 5000's 2024 list of fastest growing privately held companies in America. The company serves national cancer institutes (NCIs), academic medical centers and community based integrated delivery networks (IDNs) with the mission of delivering timely, precision cancer care.
The company delivers on this mission through AI enabled clinical and workflow solutions across three pillars of multidisciplinary collaboration, data interoperability and AI driven informatics. OncoLens' proprietary and unique oncology focused AI capabilities provide cancer centers the ability to extract key insights from structured or unstructured clinical, molecular and other lab data to find patients who might have missed treatment-defining diagnostics or therapies, in real time. OncoLens' collaboration solutions can then be used to coordinate next steps on those patients to ensure action is taken in a timely and multidisciplinary manner. The focus on a comprehensive set of solutions delivering intelligence and efficiency has set the company apart.
“Healthcare is a prime target for AI-driven innovation. Paired with the appropriate solutions, there’s incredible potential for AI to deliver useful and actionable results. We’re excited about how OncoLens continues to build impressive growth by delivering groundbreaking insights alongside innovative and AI-enabled usability tools like provider-targeted alerts.” (Mark Buffington, Managing Partner and CEO of BIP Capital)
OncoLens serves care providers internationally as well, having launched in the EMEA (Europe, Middle East and Africa) region in 2022. With the growth of its customer base, the company launched the OncoLens Research Network, partnering closely with life science commercial, real world evidence and clinical development teams to bring cutting edge research including trials and quality improvement initiatives to their centers. For life science partners, OncoLens brings a diverse, community focused network of centers to address real world evidence, diversity and inclusion in trials or finding patients with extremely rare genomic alterations or conditions.
"The past few years have been a true partnership with our provider and lifescience customers, working closely together to ensure we are able to deliver on the promise of the right treatment at the right time for every cancer patient, whether that patient is a needle in the haystack with an extremely rare genetic alteration or was one among too many that got missed for a clinical trial they were eligible for," says Anju Mathew, CEO of OncoLens. "We have a bold vision to impact cancer care and excited to continue to deliver to that vision."
OncoLens is a leading provider of digital health solutions designed to optimize cancer treatment planning. Serving more than 225 cancer centers in the U.S. and internationally, OncoLens also collaborates closely with pharmaceutical and diagnostic companies through the OncoLens Research Network. This collaboration bridges the gap between cancer centers and industry enabling the right treatment at the right time for patients. For more information on OncoLens, please visit www.oncolens.com.
.jpg)
